Lum BL - Search Results

1

MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.

Lum BL, Gosland MP. Lum BL, et al. Hematol Oncol Clin North Am. 1995 Apr;9(2):319-36. Hematol Oncol Clin North Am. 1995. PMID: 7642466 Review.

2

The effect of obesity on cyclosporine pharmacokinetics in uremic patients.

Flechner SM, Kolbeinsson MC, Lum B, Tam J, Moran T. Flechner SM, et al. Transplant Proc. 1989 Feb;21(1 Pt 2):1446-8. Transplant Proc. 1989. PMID: 2652464 No abstract available.

3

The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients.

Flechner SM, Kolbeinsson ME, Tam J, Lum B. Flechner SM, et al. Transplantation. 1989 May;47(5):806-10. doi: 10.1097/00007890-198905000-00012. Transplantation. 1989. PMID: 2655218

4

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI. Bartlett NL, et al. Among authors: lum bl. J Clin Oncol. 1994 Apr;12(4):835-42. doi: 10.1200/JCO.1994.12.4.835. J Clin Oncol. 1994. PMID: 8151326 Clinical Trial.

5

Validation of a limited sampling model to determine etoposide area under the curve.

Lum BL, Lane KJ, Synold TW, Goram A, Charnick SB, Sikic BI. Lum BL, et al. Pharmacotherapy. 1997 Sep-Oct;17(5):887-90. Pharmacotherapy. 1997. PMID: 9324178 Clinical Trial.

6

Comparison of three methods for cyclosporine area under the curve monitoring calculations.

Dalere GM, Lum BL, Cooney GF, Wong-Chin M. Dalere GM, et al. Among authors: lum bl. Ther Drug Monit. 1995 Jun;17(3):305-7. doi: 10.1097/00007691-199506000-00015. Ther Drug Monit. 1995. PMID: 7624928

7

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.

Yahanda AM, Alder KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI. Yahanda AM, et al. Among authors: lum bl. J Clin Oncol. 1992 Oct;10(10):1624-34. doi: 10.1200/JCO.1992.10.10.1624. J Clin Oncol. 1992. PMID: 1403040 Clinical Trial.

8

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI. Lum BL, et al. J Clin Oncol. 1992 Oct;10(10):1635-42. doi: 10.1200/JCO.1992.10.10.1635. J Clin Oncol. 1992. PMID: 1403041 Clinical Trial.

9

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.

Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Sikic BI, et al. Among authors: lum bl. Cancer Chemother Pharmacol. 1997;40 Suppl:S13-9. doi: 10.1007/s002800051055. Cancer Chemother Pharmacol. 1997. PMID: 9272128 Review.

10

Pharmacological considerations in the modulation of multidrug resistance.

Fisher GA, Lum BL, Hausdorff J, Sikic BI. Fisher GA, et al. Among authors: lum bl. Eur J Cancer. 1996 Jun;32A(6):1082-8. doi: 10.1016/0959-8049(96)00111-6. Eur J Cancer. 1996. PMID: 8763350 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results